Fielder Capital Group LLC Has $1.13 Million Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fielder Capital Group LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,544 shares of the medical equipment provider’s stock after acquiring an additional 43 shares during the quarter. Fielder Capital Group LLC’s holdings in Intuitive Surgical were worth $1,132,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Drive Wealth Management LLC increased its holdings in shares of Intuitive Surgical by 2.9% during the 2nd quarter. Drive Wealth Management LLC now owns 1,257 shares of the medical equipment provider’s stock worth $559,000 after acquiring an additional 36 shares during the last quarter. Tandem Investment Advisors Inc. grew its holdings in Intuitive Surgical by 1.1% in the 2nd quarter. Tandem Investment Advisors Inc. now owns 11,905 shares of the medical equipment provider’s stock valued at $5,296,000 after buying an additional 124 shares in the last quarter. Valmark Advisers Inc. grew its holdings in Intuitive Surgical by 6.4% in the 2nd quarter. Valmark Advisers Inc. now owns 909 shares of the medical equipment provider’s stock valued at $404,000 after buying an additional 55 shares in the last quarter. Retireful LLC acquired a new position in Intuitive Surgical in the 2nd quarter valued at $1,051,000. Finally, Ritholtz Wealth Management grew its holdings in Intuitive Surgical by 4.0% in the 2nd quarter. Ritholtz Wealth Management now owns 3,875 shares of the medical equipment provider’s stock valued at $1,724,000 after buying an additional 148 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,655,048.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Craig H. Barratt sold 2,496 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $402.89, for a total value of $1,005,613.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,655,048.26. The disclosure for this sale can be found here. Insiders sold 55,552 shares of company stock valued at $26,281,657 over the last 90 days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded up $5.46 on Friday, hitting $492.63. The company had a trading volume of 1,097,792 shares, compared to its average volume of 1,235,701. The firm has a market cap of $175.06 billion, a P/E ratio of 88.92, a P/E/G ratio of 5.43 and a beta of 1.39. The stock’s 50-day moving average is $454.69 and its two-hundred day moving average is $414.70. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $493.97.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the firm posted $1.18 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. Equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ISRG shares. Truist Financial upped their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Barclays upped their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Citigroup upped their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Robert W. Baird upped their target price on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. Finally, JPMorgan Chase & Co. upped their target price on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $446.45.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.